ImmunityBio (IBRX) Depreciation and Depletion (2016 - 2026)

ImmunityBio (IBRX) has 11 years of Depreciation and Depletion data on file, last reported at $3.3 million in Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $3.3 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.4 million (down 8.84% YoY), and the FY2025 annual result was $13.4 million, down 13.55% from the prior year.
• Depreciation and Depletion held at $3.3 million in Q1 2026 per IBRX's latest filing, from $3.3 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $4.6 million in Q4 2022 and troughed at $3.3 million in Q1 2025.
• A 5-year average of $3.8 million and a median of $3.9 million in 2022 frame the typical range for Depreciation and Depletion.
• The sharpest annual moves came in 2022 and 2025: Depreciation and Depletion grew 27.78% in 2022, then decreased 17.5% in 2025.
• A 5-year view of Depreciation and Depletion shows it stood at $4.6 million in 2022, then fell by 10.87% to $4.1 million in 2023, then slipped by 12.2% to $3.6 million in 2024, then declined by 8.33% to $3.3 million in 2025, then changed by 0.0% to $3.3 million in 2026.
• Business Quant data shows IBRX's Depreciation and Depletion at $3.3 million in Q1 2026, $3.3 million in Q4 2025, and $3.4 million in Q3 2025.